Antigen presentation in cancer: insights into tumour ... - Nature
2021年3月9日 · Cancer rejection antigens are the targets of antitumour T cells. Candidates for such rejection antigens include tumour-associated antigens (TAAs; Box 1 ), viral antigens and...
Tumour immune rejection triggered by activation of α2 ... - Nature
2023年6月7日 · Here we show that agonists of α2-adrenergic receptors (α2-AR) have very strong anti-tumour activity when used as monotherapies in multiple immunocompetent tumour models, including ICB-resistant...
Tumor Rejection Antigen - an overview | ScienceDirect Topics
Tumors may express antigens that can become targets of antigen-specific T cell responses that lead to tumor rejection. These tumor rejection antigens, which include tumor-specific antigens, cancer-testis antigens, and differentiation antigens, have been exploited for therapeutic purposes including for cancer vaccines, where patients are ...
Uncovering the Tumor Antigen Landscape: What to Know about …
2020年6月23日 · The current review is intended to define what are today known as tumor antigens, with a main focus on CTL antigenic peptides. We also review the techniques developed and employed to date for antigen discovery, exploring both the direct elution of HLA-I peptides and the in silico prediction of epitopes.
Identification of tumor antigens with immunopeptidomics
2021年10月11日 · We review current methods for the identification and validation of tumor antigens, focusing on recent developments in proteogenomics and MS-based immunopeptidomics for the discovery of ...
Hitting the target: how T cells detect and eliminate tumors
2018年1月1日 · Van der Bruggen and colleagues identified the first human tumor antigen, MAGE-1, a cancer/testis antigen (CTA) recognized by endogenous T cells. CTAs are expressed in testes, fetal ovaries, or trophoblasts, but are otherwise absent in healthy somatic cells.
Using the immune response to attack tumors - Immunobiology
Tumor rejection antigens are peptides of tumor-cell proteins that are presented to T cells by MHC molecules. These peptides can become the targets of a tumor-specific T-cell response because they are not displayed on the surface of normal cells, at least not at levels sufficient to be recognized by T cells.
Targeting Tumor-Rejection Antigens in Melanoma With Tumor …
2021年6月4日 · Immunologists have long searched for tumor-rejection antigens: molecules on tumor cells, but not on normal tissues, that could be recognized by the immune system and would lead the immune system to reject the tumor. The hope was that tumor-rejection antigens would be common to tumor types and shared across patients.
Neoantigens in cancer immunotherapy | Science - AAAS
2015年4月3日 · A second class of potential cancer rejection antigens is formed by peptides that are entirely absent from the normal human genome, so-called neoantigens. For the large group of human tumors without a viral etiology, such neo-epitopes are solely created by tumor-specific DNA alterations that result in the formation of novel protein sequences.
Tumor neoantigens: from basic research to clinical applications
2019年9月6日 · Tumor neoantigen, or tumor-specific antigen (TSA), is the repertoire of peptides that displays on the tumor cell surface and could be specifically recognized by neoantigen-specific T cell receptors (TCRs) in the context of major histocompatibility complexes (MHCs) molecules [1, 2, 3, 4, 5].